Abstract 135P
Background
In latest Japanese guidelines for gastric cancer treatment, the curability of endoscopic resection of patients with lymphovascular invasion (LVI) is classified as C-2 regardless of the presence or absence of other risk factors, and the standard therapy for C-2 is additional radical resection. On the other hand, pathological diagnosis after additional resection is often diagnosed as pN0, resulting in over treatment. The aim of this study was to investigate the clinical significance of LVI in the indication of endoscopic resection for gastric cancer, and also to evaluate the recently proposed stratification using the eCura system, a new scoring system for post-ESD curability of early gastric cancer.
Methods
A total of 164 patients who underwent additional surgical resection after endoscopic resection were enrolled in this study. The correlation between LVI and pathological lymph node metastasis was investigated and compared with the eCura system score.
Results
Patients with LVI positive (LVI (+)) were 64, and 100 were LVI negative (LVI (-)). Only 12 (7.3%) had lymph node metastasis, 8 (12.5%) in the LVI (+) and 4 (4.0%) in the LVI (-) (p = 0.04). In 9 cases, additional resection was indicated only by LVI, and none of the lymph node metastases was observed. The risk assessment using eCura system for all cases were low / intermediate / high risk: 103 (62.8%) / 42 (25.6%) / 19 (11.6%). The positive rate of lymph node metastasis was 4 (3.9%) / 4 (9.5%) / 4 (21.1%) respectively. Of the 9 cases resected by LVI alone, there were no cases classified as high risk.
Conclusions
Indications for additional surgical resection based on LVI alone are likely to be over treatment, and in such cases, careful judgment is required with reference to evaluation by the eCura system.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session
275P - Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
Presenter: Vivek Agarwala
Session: e-Poster Display Session